Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (110)
Cancellation by sponsor (70)
Prescription medicine registration (59)
Australian public assessment report (AusPar) (47)
Designation or determination (24)
Prescription medicine decision summary (11)
Prescription medicine evaluation (8)
Section 14, TGO91 consent (1)

Date

2026 (7)
2025 (33)
2024 (28)
2023 (31)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (6)
2012 (3)
2011 (5)
2010 (4)
2008 (3)
2006 (5)
2004 (2)
2003 (5)
2002 (2)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Search

Sponsor content

330 result(s) found, displaying 261 to 270

XYLOCAINE 2% With Adrenaline 1:80,000 (Ampoule) (Lignocaine + Adrenaline) Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
Xylocaine 5% Adhesive Ointment (lignocaine) Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
XYLOCAINE 1.5% lignocaine hydrochloride 375mg/25mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
MARCAIN 0.75% bupivacaine hydrochloride 75mg/10mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
MARCAIN 0.375% bupivacaine hydrochloride 37.5mg/10mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
XYLOCAINE 1.5% lignocaine hydrochloride 300mg/20mL injection ampoule Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
IRESSA GEFITINIB 250 mg tablet - film coated blister pack Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
INDERAL PROPANOLOL HYDROCHLORIDE 10 mg tablet - film coated bottle Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
INDERAL PROPANOLOL HYDROCHLORIDE 40mg tablet - film coated bottle Cancelled under s30(1)(c) of the Act

19 November 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
VIMOVO naproxen and esomeprazole 500mg/20mg modified release tablet bottle Cancelled under s30(1)(c )

4 September 2015

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd

Pages

First page
Previous page
…
Page 23
Page 24
Page 25
Page 26
Current page 27
Page 28
Page 29
Page 30
Page 31
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.